Bremelanotide (PT-141) and low sexual desire
The FDA reviewed Vyleesi as a specific bremelanotide injection for premenopausal women with acquired, generalized HSDD. The trials measured desire and distress. The groups did not differ significantly in the number of satisfying sexual experiences, a separate measure.
Sources for this section
Ganirelix and cetrorelix during IVF
Ganirelix acetate and cetrorelix acetate block the action of gonadotropin-releasing hormone, a signal that can lead to early ovulation. Their labels describe prevention of a premature hormone surge during monitored ovarian stimulation. The labels answer an IVF timing question. A fertility clinic can explain how that fits the overall chance of a live birth for the individual cycle.
Kisspeptin-54 for sexual desire and egg maturation
In a small randomized study, 32 premenopausal women with HSDD completed visits with kisspeptin-54 given by vein and with placebo. The primary measures were brain responses to sexual and attraction cues during the visits. The study found differences in brain activity and some self-reported responses. Whether repeated treatment produces lasting relief in daily life remains open.
A separate phase 2 study used kisspeptin-54 as an egg-maturation trigger in IVF patients at high risk of ovarian hyperstimulation, an excessive response to fertility medicines. It studied mature eggs in a closely monitored fertility clinic. These experiments used kisspeptin-54. FDA has raised potential safety concerns about compounded formulations containing the shorter kisspeptin-10, including possible immune reactions and impurities.
Oxytocin claims and what is actually in the product
A randomized study of intranasal oxytocin in women with sexual dysfunction found similar improvements over time with oxytocin and placebo. It provides little basis for expecting a marketed oxytocin spray to improve sexual function.
Check whether a claim refers to the exact finished product and route studied. An approved prescription product has a specific label, strength and form. FDA does not approve compounded products or verify their safety, effectiveness or quality before marketing. FDA has also cited sellers for marketing unapproved bremelanotide despite research-use-only labeling.